<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39373955</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0305</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Molecular biotechnology</Title><ISOAbbreviation>Mol Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Exploring Niclosamide as a Multi-target Drug Against SARS-CoV-2: Molecular Dynamics Simulation Studies on Host and Viral Proteins.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12033-024-01296-2</ELocationID><Abstract><AbstractText>Niclosamide has emerged as a promising repurposed drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In vitro studies suggested that niclosamide inhibits the host transmembrane protein 16F (hTMEM16F), crucial for lipid scramblase activity, which consequently reduces syncytia formation that aids viral spread. Based on other in vitro reports, niclosamide may also target viral proteases such as papain-like protease (PLpro) and main protease (Mpro), essential for viral replication and maturation. However, the precise interactions by which niclosamide interacts with these multiple targets remain largely unclear. Docking and molecular dynamics (MD) simulation studies were undertaken based on a homology model of the hTMEM16F and available crystal structures of SARS-CoV-2 PLpro and Mpro. Niclosamide was observed to bind stably throughout a 400 ns MD simulation at the extracellular exit gate of the hTMEM16F tunnel, forming crucial interactions with residues spanning the TM1-TM2 loop (Gln350), TM3 (Phe481), and TM5-TM6 loop (Lys573, Glu594, and Asp596). Among the SARS-CoV-2 proteases, niclosamide was found to interact effectively with conserved active site residues of PLpro (Tyr268), exhibiting better stability in comparison to the control inhibitor, GRL0617. In conclusion, our in silico analyses support niclosamide as a multi-targeted drug inhibiting viral and host proteins involved in SARS-CoV-2 infections.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jagtap</LastName><ForeName>Prachi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bioinformatics &amp; Data Management Group, ICMR National Institute of Virology, 20A Dr. Ambedkar Road, Pune, Maharashtra, 411 001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Meena</LastName><ForeName>Virendra Kumar</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>ICMR National Institute of Virology, 20A Dr. Ambedkar Road, Pune, Maharashtra, 411 001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sambhare</LastName><ForeName>Susmit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ICMR National Institute of Virology, 20A Dr. Ambedkar Road, Pune, Maharashtra, 411 001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Atanu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ICMR National Institute of Virology, 20A Dr. Ambedkar Road, Pune, Maharashtra, 411 001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherian</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9629-3490</Identifier><AffiliationInfo><Affiliation>Bioinformatics &amp; Data Management Group, ICMR National Institute of Virology, 20A Dr. Ambedkar Road, Pune, Maharashtra, 411 001, India. sarahcherian100@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>3/1/3/JRF-2019/HRD-057(29252)</GrantID><Agency>Indian Council of Medical Research</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Mol Biotechnol</MedlineTA><NlmUniqueID>9423533</NlmUniqueID><ISSNLinking>1073-6085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Docking</Keyword><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Lipid scramblase</Keyword><Keyword MajorTopicYN="N">MD simulation</Keyword><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">Niclosamide</Keyword><Keyword MajorTopicYN="N">PLpro</Keyword><Keyword MajorTopicYN="N">Protease inhibitor</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">hTMEM16F</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373955</ArticleId><ArticleId IdType="doi">10.1007/s12033-024-01296-2</ArticleId><ArticleId IdType="pii">10.1007/s12033-024-01296-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li, Q., Guan, X., Wu, P., et al. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine, 382, 1199–1207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Y., Wang, J., Li, F., &amp; Shi, Y. (2020). Main clinical features of COVID-19 and potential prognostic and therapeutic value of the microbiota in SARS-CoV-2 Infections. Frontiers in Microbiology, 11, 1302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J.F.-W., Yuan, S., Chu, H., Sridhar, S., &amp; Yuen, K.-Y. (2024). COVID-19 drug discovery and treatment options. Nature Reviews Microbiology, 22, 391–407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-024-01036-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., &amp; Al-Nasser, A. D. (2020). SARS-CoV-2 and Coronavirus disease 2019: What we know so far. Pathogens, 9, 231.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens9030231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch, B. J., van der Zee, R., de Haan, C. A. M., &amp; Rottier, P. J. M. (2003). The Coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. Journal of Virology, 77, 8801–8811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.16.8801-8811.2003</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, W., Moore, M. J., Vasilieva, N., et al. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426, 450–454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Guo, Y., Pan, Y., &amp; Zhao, Z. J. (2020). Structure analysis of the receptor binding of 2019-nCoV. Biochemical and Biophysical Research Communications, 525, 135–140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.02.071</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., &amp; Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181, 281-292.e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko, M., Marzi, A., &amp; Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology, 5, 562–569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0688-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga, L., Ali, H., Secco, I., et al. (2021). Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature, 594, 88–93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03491-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Le, T., Jia, Z., Le, S. C., Zhang, Y., Chen, J., &amp; Yang, H. (2019). An inner activation gate controls TMEM16F phospholipid scrambling. Nature Communications, 10, 1846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09778-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburn, T. T., &amp; Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3, 673–683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1468</ArticleId></ArticleIdList></Reference><Reference><Citation>Shyr, Z. A., Gorshkov, K., Chen, C. Z., &amp; Zheng, W. (2020). Drug discovery strategies for SARS-CoV-2. Journal of Pharmacology and Experimental Therapeutics, 375, 127–138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.120.000123</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, S., Weiss, A., Goodman, J., Fisk, M., Kulkarni, S., Lu, I., Gray, J., Smith, R., Sommer, M., &amp; Cheriyan, J. (2022). Niclosamide—a promising treatment for COVID-19. British J Pharmacology, 179, 3250–3267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15843</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunaugh, A. D., Seo, H., Warnken, Z., Ding, L., Seo, S. H., &amp; Smyth, H. D. C. (2021). Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. PLoS ONE, 16, e0246803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246803</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hadiya, B. M. H. (2005). Niclosamide: Comprehensive profile. Profiles of drug substances, excipients and related methodology (pp. 67–96). Elsevier.</Citation></Reference><Reference><Citation>Weinbach, E. C., &amp; Garbus, J. (1969). Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature, 221, 1016–1018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/2211016a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tharmalingam, N., Port, J., Castillo, D., &amp; Mylonakis, E. (2018). Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Science and Reports, 8, 3701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22037-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Z., Brecher, M., Deng, Y.-Q., et al. (2017). Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Research, 27, 1046–1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2017.88</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao, J.-C., HuangFu, W.-C., Tsai, T.-T., Ho, M.-R., Jhan, M.-K., Shen, T.-J., Tseng, P.-C., Wang, Y.-T., &amp; Lin, C.-F. (2018). The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. PLoS Neglected Tropical Diseases, 12, e0006715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006715</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Bar, H. M., Abdallah, I. A., Fayed, M. A. A., Moatasim, Y., Mostafa, A., El-Behairy, M. F., Elimam, H., Elshaier, Y. A. M. M., &amp; Abouzid, K. A. M. (2021). Lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies. RSC Advances, 11, 28876–28891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1RA04576H</ArticleId></ArticleIdList></Reference><Reference><Citation>Samrat, S. K., Xu, J., Xie, X., et al. (2022). Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Research, 205, 105381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105381</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone, M. E., Malvezzi, M., Lee, B.-C., &amp; Accardi, A. (2018). Known structures and unknown mechanisms of TMEM16 scramblases and channels. Journal of General Physiology, 150, 933–947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.201711957</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, Y., Schreiber, R., &amp; Kunzelmann, K. (2012). Anoctamins are a family of Ca<sup>2+</sup> activated Cl<sup>−</sup> channels. Journal of Cell Science. https://doi.org/10.1242/jcs.109553</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.109553</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock, J. M., &amp; Hartzell, H. C. (2017). Anoctamins/TMEM16 proteins: Chloride channels flirting with lipids and extracellular vesicles. Annual Review of Physiology, 79, 119–143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-022516-034031</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, P. (2015). Phospholipid scramblases. Lipid Insights, 8s1, LPI.S31785.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/LPI.S31785</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock, J. M., &amp; Hartzell, H. C. (2016). A pore idea: The ion conduction pathway of TMEM16/ANO proteins is composed partly of lipid. Pflügers Archiv - European Journal of Physiology, 468, 455–473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-015-1777-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, S., Pang, C., Guo, S., Chen, Y., Ma, B., Qu, C., Ji, Q., &amp; An, H. (2020). Recent progress in structural studies on TMEM16A channel. Computational and Structural Biotechnology Journal, 18, 714–722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2020.03.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalienkova, V., ClericoMosina, V., &amp; Paulino, C. (2021). The Groovy TMEM16 family: Molecular mechanisms of lipid scrambling and ion conduction. Journal of Molecular Biology, 433, 166941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.166941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevers, E. M., &amp; Williamson, P. L. (2016). Getting to the outer leaflet: Physiology of phosphatidylserine exposure at the plasma membrane. Physiological Reviews, 96, 605–645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00020.2015</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, J., Umeda, M., Sims, P. J., &amp; Nagata, S. (2010). Calcium-dependent phospholipid scrambling by TMEM16F. Nature, 468, 834–838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09583</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvezzi, M., Chalat, M., Janjusevic, R., Picollo, A., Terashima, H., Menon, A. K., &amp; Accardi, A. (2013). Ca2+-dependent phospholipid scrambling by a reconstituted TMEM16 ion channel. Nature Communications, 4, 2367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3367</ArticleId></ArticleIdList></Reference><Reference><Citation>Scudieri, P., Caci, E., Venturini, A., Sondo, E., Pianigiani, G., Marchetti, C., Ravazzolo, R., Pagani, F., &amp; Galietta, L. J. V. (2015). Ion channel and lipid scramblase activity associated with expression of TMEM16F/ANO6 isoforms: TMEM16F variants. Journal of Physiology, 593, 3829–3848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP270691</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner, J. D., Lim, N. K., Schenck, S., Duerst, A., &amp; Dutzler, R. (2014). X-ray structure of a calcium-activated TMEM16 lipid scramblase. Nature, 516, 207–212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13984</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone, M. E., Rheinberger, J., Lee, B.-C., et al. (2019). Structural basis of Ca2+-dependent activation and lipid transport by a TMEM16 scramblase. eLife, 8, e43229.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43229</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalienkova, V., ClericoMosina, V., Bryner, L., Oostergetel, G. T., Dutzler, R., &amp; Paulino, C. (2019). Stepwise activation mechanism of the scramblase nhTMEM16 revealed by cryo-EM. eLife, 8, e44364.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.44364</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrant, J. D, McCammon, J. A (2011) Molecular dynamics simulations and drug discovery. BMC Biol 9, 71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7007-9-71</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi, A. A. T., Mohammad, T., Hasan, G. M., &amp; Hassan, Md. I. (2018). Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. CTMC, 18, 1755–1768.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026618666181025114157</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfiky, A. A. (2020). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2020.1761882</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1761882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty, R., Bhattacharje, G., Baral, J., et al. (2022). In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. Computers in Biology and Medicine, 147, 105788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2022.105788</ArticleId></ArticleIdList></Reference><Reference><Citation>The UniProt Consortium. (2017). UniProt: The universal protein knowledgebase. Nucleic Acids Research, 45, D158–D169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1099</ArticleId></ArticleIdList></Reference><Reference><Citation>Altschul, S. F., Gish, W., Miller, W., Myers, E. W., &amp; Lipman, D. J. (1990). Basic local alignment search tool. Journal of Molecular Biology, 215, 403–410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(05)80360-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwede, T. (2003). SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Research, 31, 3381–3385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg520</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman, H. M. (2000). The protein data bank. Nucleic Acids Research, 28, 235–242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi, K. A., Weigelt, C. A., Nayeem, A., &amp; Krystek, S. R. (2007). Loopholes and missing links in protein modeling. Protein Science, 16, 1999–2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.072887807</ArticleId></ArticleIdList></Reference><Reference><Citation>MadhaviSastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., &amp; Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27, 221–234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-013-9644-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., &amp; Friesner, R. A. (2004). A hierarchical approach to all-atom protein loop prediction. Proteins, 55, 351–367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.10613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapusta, K., Kar, S., Collins, J. T., Franklin, L. M., Kolodziejczyk, W., Leszczynski, J., &amp; Hill, G. A. (2021). Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (M<sup>pro</sup>) through docking, molecular mechanic &amp; dynamic, and ADMET profiling. Journal of Biomolecular Structure and Dynamics, 39, 6810–6827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1806930</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger Release 2020-3: Maestro, Schrödinger, LLC, New York, NY, 2020.</Citation></Reference><Reference><Citation>Pitsillou, E., Liang, J., Ververis, K., Lim, K. W., Hung, A., &amp; Karagiannis, T. C. (2020). Identification of small molecule inhibitors of the deubiquitinating activity of the SARS-CoV-2 papain-like protease: In silico molecular docking studies and in vitro enzymatic activity assay. Frontiers in Chemistry, 8, 623971.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.623971</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengist, H. M., Dilnessa, T., &amp; Jin, T. (2021). Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Frontiers in Chemistry, 9, 622898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.622898</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen, W. L., &amp; Tirado-Rives, J. (1988). The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. Journal of the American Chemical Society, 110, 1657–1666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja00214a001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, S., Thiessen, P. A., Bolton, E. E., et al. (2016). PubChem substance and compound databases. Nucleic Acids Research, 44, D1202–D1213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv951</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger Release 2020-3: LigPrep, Schrödinger, LLC, New York, 2020.</Citation></Reference><Reference><Citation>Johnston, R. C., Yao, K., Kaplan, Z., et al. (2023). Epik: P K <sub>a</sub> and protonation state prediction through machine learning. Journal of Chemical Theory and Computation, 19, 2380–2388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.3c00044</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon, S. L., Smondyrev, A. M., &amp; Rao, S. N. (2006). PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chemical Biology &amp; Drug Design, 67, 370–372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-0285.2006.00384.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren, T. (2007). New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Design, 69, 146–148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-0285.2007.00483.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesner, R. A., Banks, J. L., Murphy, R. B., et al. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47, 1739–1749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0306430</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., &amp; Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. Journal of Medicinal Chemistry, 49, 6177–6196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm051256o</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers, K. J., Sacerdoti, F. D., Salmon, J. K., et al. (2006). Molecular dynamics—scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the 2006 ACM/IEEE conference on Supercomputing - SC ’06. ACM Press, Tampa, p 84</Citation></Reference><Reference><Citation>Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., &amp; Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79, 926–935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.445869</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen, W. L., Maxwell, D. S., &amp; Tirado-Rives, J. (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society, 118, 11225–11236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9621760</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gunsteren, W. F., &amp; Berendsen, H. J. C. (1982). Algorithms for brownian dynamics. Molecular Physics, 45, 637–647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00268978200100491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Y., Tepper, H. L., &amp; Voth, G. A. (2006). Flexible simple point-charge water model with improved liquid-state properties. The Journal of Chemical Physics, 124, 024503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.2136877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalibaeva, G., Ferrario, M., &amp; Ciccotti, G. (2003). Constant pressure-constant temperature molecular dynamics: A correct constrained NPT ensemble using the molecular virial. Molecular Physics, 101, 765–778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0026897021000044025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuckerman, M., Berne, B. J., &amp; Martyna, G. J. (1992). Reversible multiple time scale molecular dynamics. The Journal of Chemical Physics, 97, 1990–2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.463137</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathaneni, V., Kulkarni, N. S., Muth, A., &amp; Gupta, V. (2019). Drug repurposing: A promising tool to accelerate the drug discovery process. Drug Discovery Today, 24, 2076–2085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.06.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E., &amp; Bolognesi, M. L. (2018). A perspective on multi-target drug discovery and design for complex diseases. Clinical &amp; Translational Medicine, 7, e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-017-0181-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., &amp; Prasad, S. V. U. M. (2018). Dual or multi-targeting inhibitors: The next generation anticancer agents. European Journal of Medicinal Chemistry, 143, 1277–1300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.10.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, J.-X., Ding, K., &amp; Wang, C.-Y. (2012). Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chinese Journal of Cancer, 31, 178–184.</Citation><ArticleIdList><ArticleId IdType="doi">10.5732/cjc.011.10290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassen, N. C., Niemeyer, D., Muth, D., et al. (2019). SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nature Communications, 10, 5770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13659-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassen, N. C., Papies, J., Bajaj, T., et al. (2021). SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nature Communications, 12, 3818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24007-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulamir, A. S., Gorial, F. I., Saadi, S. J., Maulood, M. F., Hashim, H. A., Alnuaimi, A. S., &amp; Abdulrrazaq, M. K. (2021). A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management. Annals of Medicine &amp; Surgery. https://doi.org/10.1016/j.amsu.2021.102779</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2021.102779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrita, I., Benedetto, R., Schreiber, R., &amp; Kunzelmann, K. (2019). Niclosamide repurposed for the treatment of inflammatory airway disease. JCI Insight, 4, e128414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.128414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaitseva, E., Zaitsev, E., Melikov, K., Arakelyan, A., Marin, M., Villasmil, R., Margolis, L. B., Melikyan, G. B., &amp; Chernomordik, L. V. (2017). Fusion stage of HIV-1 entry depends on virus-induced cell surface exposure of phosphatidylserine. Cell Host &amp; Microbe, 22, 99-110.e7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, S., Puchades, C., Ko, J., et al. (2023). Identification of a drug binding pocket in TMEM16F calcium-activated ion channel and lipid scramblase. Nature Communications, 14, 4874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40410-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Le, S. C., Jia, Z., Chen, J., &amp; Yang, H. (2019). Molecular basis of PIP2-dependent regulation of the Ca<sup>2+</sup>-activated chloride channel TMEM16A. Nature Communications, 10, 3769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11784-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, Z., &amp; Chen, J. (2021). Specific PIP2 binding promotes calcium activation of TMEM16A chloride channels. Communications Biology, 4, 259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01782-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm, T., Ebert, G., Calleja, D. J., et al. (2020). Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO Journal. https://doi.org/10.15252/embj.2020106275</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106275</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangavel, N., &amp; Albratty, M. (2023). Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids. Journal of King Saud University - Science, 35, 102402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jksus.2022.102402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>